Revelation Biosciences (NASDAQ:REVB – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.04), FiscalAI reports.
Revelation Biosciences Trading Up 1.8%
REVB traded up $0.02 on Friday, hitting $1.14. 25,572 shares of the company’s stock were exchanged, compared to its average volume of 42,163. Revelation Biosciences has a fifty-two week low of $0.88 and a fifty-two week high of $11.72. The stock has a market cap of $4.46 million, a price-to-earnings ratio of -0.09 and a beta of -0.15. The firm has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.27.
Institutional Trading of Revelation Biosciences
A hedge fund recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC purchased a new position in shares of Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned 2.15% of Revelation Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 12.80% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Report on Revelation Biosciences
About Revelation Biosciences
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
Further Reading
- Five stocks we like better than Revelation Biosciences
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
